NCT02268253 2025-01-06
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Stemline Therapeutics, Inc.
Phase 1/2 Completed
Clinical Trials
4 trialsNCT02270463 2024-10-17
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Stemline Therapeutics, Inc.
Phase 1/2 Terminated
NCT02113982 2024-08-01
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT02661022 2024-04-17
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Stemline Therapeutics, Inc.
Phase 1/2 Terminated